Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11183816 | 0.79 | SRC (0.48) | SRCCYP2D6LMNAMAPK1CES2 | |
| SCHEMBL2962887 | 0.77 | — | — | |
| SCHEMBL28232476 | 0.76 | SRC (0.56) | SRCCYP2D6LMNAMAPK1CES2 | |
| SCHEMBL9394507 | 0.76 | SRC (0.50) | SRCCYP2D6LMNAMAPK1CES2 | |
| SCHEMBL1100039 | 0.76 | TRPA1 (0.42) | SRCCYP2D6DPP4LMNA | |
| SCHEMBL9953863 | 0.76 | IDO1 (0.41) | LMNACES2CES1 | |
| SCHEMBL28232530 | 0.76 | SRC (0.56) | SRCCYP2D6LMNAMAPK1CES2 | |
| SCHEMBL241909 | 0.76 | SRC (0.56) | SRCCYP2D6LMNAMAPK1CES2 | |
| SCHEMBL7798252 | 0.74 | CHRNA7 (0.41) | LMNACES2CES1 | |
| SCHEMBL6969665 | 0.74 | SRC (0.48) | SRCCYP2D6LMNAMAPK1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421826-B1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | claimed |
| US-8283357-B2 | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-10-09 | — | — | US | claimed |
| US-8252815-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2012-08-28 | — | — | US | claimed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | claimed |
| US-20120095049-A1 | NOCICEPTIN ANALOGS | PURDUE PHARMA L.P. (US) | 2012-04-19 | — | — | US | claimed |
| EP-2440517-A2 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-04-18 | — | — | EP | claimed |
| EP-2421826-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | claimed |
| EP-2318363-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | Nuevolution A/S (DK) | 2011-05-11 | — | — | EP | claimed |
| WO-2010144378-A2 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-12-16 | — | — | WO | claimed |
| US-20100311794-A1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-12-09 | — | — | US | claimed |
| US-20030069249-A1 | Nociceptin analogs | PURDUE PHARMA L.P. | 2003-04-10 | — | — | US | claimed |
| US-20030027834-A1 | Spiropyrazole compounds | PURDUE PHARMA L.P. | 2003-02-06 | — | — | US | claimed |
| US-20030018041-A1 | Spiroindene and spiroindane compounds | PURDUE PHARMA L.P. | 2003-01-23 | — | — | US | claimed |
| US-20030013874-A1 | Nociceptin analogs | PURDUE PHARMA L.P | 2003-01-16 | — | — | US | claimed |
| US-20030008886-A1 | Benzimidazolone compounds | PURDUE PHARMA L.P. | 2003-01-09 | — | — | US | claimed |
| WO-2002085355-A1 | SPIROPYRAZOLE COMPOUNDS | EURO-CELTIQUE, S.A. (LU) | 2002-10-31 | — | — | WO | claimed |
| WO-2002085354-A1 | SPIROINDENE AND SPIROINDANE COMPOUNDS | EURO-CELTIQUE S.A. (LU) | 2002-10-31 | — | — | WO | claimed |
| WO-2002085357-A1 | NOCICEPTIN ANALOGS | EURO-CELTIQUE, S.A. (LU) | 2002-10-31 | — | — | WO | claimed |
| WO-2002085291-A2 | NOCICEPTIN ANALOGS | EURO-CELTIQUE, S.A. (LU) | 2002-10-31 | — | — | WO | claimed |
| WO-2002085361-A1 | BENZIMIDAZOLONE COMPOUNDS | EURO-CELTIQUE, S.A. (LU) | 2002-10-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008886-A1 | Benzimidazolone compounds | MRPS28, B2M, CCNI | SRC 2820/4885CYP2D6 382/4885DPP4 1889/4885 |
| US-20030013874-A1 | Nociceptin analogs | OPRL1, OPRK1, NPBWR1 | SRC 3377/4885CYP2D6 2628/4885DPP4 4390/4885 |
| US-20100311794-A1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC3 | SRC 3133/4885CYP2D6 4042/4885DPP4 1546/4885 |
| US-20120095049-A1 | NOCICEPTIN ANALOGS | OPRL1, NPY1R, NPBWR1 | SRC 3368/4885CYP2D6 3009/4885DPP4 4097/4885 |
| US-20030027834-A1 | Spiropyrazole compounds | REN, ADRA1B, NR3C2 | SRC 3181/4885CYP2D6 106/4885DPP4 2192/4885 |
| US-20030069249-A1 | Nociceptin analogs | OPRL1, NPY1R, OPRK1 | SRC 3662/4885CYP2D6 2976/4885DPP4 4164/4885 |
| US-20030018041-A1 | Spiroindene and spiroindane compounds | NR3C2, REN, NR1I2 | SRC 3642/4885CYP2D6 570/4885DPP4 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.